Arginine deprivation as a new treatment strategy for head and neck cancer

Oral Oncology

Volumn 48, Issue 12, 2012, Pages 1227-1235

  Huang, Cheng Chih ^a   Tsai, Sen Tien ^a,b   Kuo, Ching Chuan ^c   Chang, Jeffrey S ^c   Jin, Ying Tai ^d   Chang, Jang Yang ^c   Hsiao, Jenn Ren ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b Tainan Hospital   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d Department of Pathology   (Taiwan)

Author keywords

Arginine; Argininosuccinate synthetase (ASS); Head and neck cancer; Immunohistochemistry (IHC); Oral squamous cell carcinoma (OSCC)

Indexed keywords

ARGININE; ARGININE DEIMINASE; ARGININOSUCCINATE SYNTHASE;

ADULT; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DIET THERAPY; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; ARGININE; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA; HEAD AND NECK NEOPLASMS; HUMANS; HYDROLASES; IMMUNOHISTOCHEMISTRY; MIDDLE AGED;

EID: 84869507054     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2012.06.004     Document Type: Article

References (36)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2 2005 74 108
2. M.D. Mignogna, S. Fedele, and L. Lo Russo The world cancer report and the burden of oral cancer Eur J Cancer Prev 13 2 2004 139 142
3. N. Denaro, E.G. Russi, V. Adamo, I. Colantonio, and M.C. Merlano Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions Oncology 81 1 2011 21 29
4. C.J. Langer Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications Cancer 112 12 2008 2635 2645
5. G. Wu, and S.M. Morris Jr. Arginine metabolism: nitric oxide and beyond Biochem J 336 1 1998 1 17
6. A. Husson, C. Brasse-Lagnel, A. Fairand, S. Renouf, and A. Lavoinne Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle Eur J Biochem 270 9 2003 1887 1899
7. L. Feun, M. You, C.J. Wu, M.T. Kuo, M. Wangpaichitr, and S. Spector Arginine deprivation as a targeted therapy for cancer Curr Pharm Des 14 11 2008 1049 1057
8. K. Miyazaki, H. Takaku, M. Umeda, T. Fujita, W. Huang, and T. Kimura Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line Cancer Res 50 15 1990 4522 4527
9. C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski, and M.A. Clark Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanoma and hepatocellular carcinomas in vitro and in vivo Cancer Res 62 19 2002 5443 5450
10. P.W. Szlosarek, A. Klabatsa, A. Pallaska, M. Sheaff, P. Smith, and T. Crook In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion Clin Cancer Res 12 23 2006 7126 7131
11. C.Y. Yoon, Y.J. Shim, E.H. Kim, J.H. Lee, N.H. Won, and J.H. Kim Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase Int J Cancer 120 4 2007 897 905
12. P.N.M. Cheng, T.L. Lam, W.M. Lam, S.M. Tsui, A.W.M. Cheng, and W.H. Lo Pegylated recombinant human arginase (rhArg-peg 5,000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion Cancer Res 67 1 2007 309 317
13. T.L. Bowles, R. Kim, J. Galante, C.M. Parsons, S. Virudachalam, and H.J. Kung Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase Int J Cancer 123 8 2008 1950 1955
14. R.H. Kim, J.M. Coates, T.L. Bowles, G.P. McNerney, J. Sutcliffe, and J.U. Jung Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase independent apoptosis Cancer Res 69 2 2009 700 708
15. L.J. Shen, W.C. Lin, K. Beloussow, and W.C. Shen Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase Cancer Lett 191 2 2003 165 170
16. W.B. Tsai, I. Aiba, S.Y. Lee, L. Feun, N. Savaraj, and M.T. Kuo Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4 Mol Cancer Ther 8 12 2009 3223 3233
17. B.J. Dillon, V.G. Prieto, S.A. Curley, C.M. Ensor, F.W. Holtsberg, and J.S. Bomalaski Incidence and distribution of argininosuccinate synthetase deficiency in human cancers Cancer 100 4 2004 826 833
18. P.A. Ascierto, S. Scala, G. Castello, A. Daponte, E. Simeone, and A. Ottaiano Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies J Clin Oncol 23 30 2005 7660 7668
19. F. Izzo, P. Marra, G. Beneduce, G. Castello, P. Vallone, and V. De Rosa Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies J Clin Oncol 22 10 2004 1815 1822
20. E.S. Glazer, M. Piccirillo, V. Albino, R. Di Giacomo, R. Palaia, and A.A. Mastro Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma J Clin Oncol 28 13 2010 2220 2226
21. T.S. Yang, S.N. Lu, Y. Chao, I.S. Sheen, C.C. Lin, and T.E. Wang A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients Br J Cancer 103 7 2010 954 960
22. E. Kobayashi, M. Masuda, R. Nakayama, H. Ichikawa, R. Satow, and M. Shitashige Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma Mol Cancer Ther 9 3 2010 535 544
23. S.M. Lagarde, P.E. Ver Loren van Themaat, P.D. Moerland, L.A. Gilhuijs-Pederson, F.J.W. ten Kate, and P.H. Reitsma Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus Ann Surg Oncol 15 12 2008 3459 3470
24. F.L. Greene, D.L. Page, I.D. Fleming, A.G. Fritz, C.M. Balch, and D.G. Haller American joint committee on cancer staging manual for staging of cancer 6th ed. 2002 J.B. Lippincott Philadelphia
25. G. Cordella, H.T. Luebbers, V. Rivelli, K.W. Grätz, and A.L. Kruse An evaluation of the preoperative hemoglobin level as a prognostic factor for oral squamous cell carcinoma Head Neck Oncol 3 2011 35
26. B. Delage, D.A. Fennell, L. Nicholson, I. McNeish, N.R. Lemoine, and T. Crook Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer Int J Cancer 126 12 2010 2762 2772
27. D.N. Wheatley Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells Semin Cancer Biol 15 4 2005 247 253
28. L.J. Nicholson, P.R. Smith, L. Hiller, P.W. Szlosarek, C. Kimberley, and J. Sehouli Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer Int J Cancer 125 6 2009 1454 1463
29. T.M. Goldson, Y. Han, K.B. Knight, H.L. Weiss, and V.A. Resto Clinicopathological predictors of lymphatic metastasis in HNSCC: implications for molecular mechanisms of metastatic disease J Exp Ther Oncol 8 3 2010 211 221
30. J. Helleman, M.P. Jansen, P.N. Span, I.L. van Staveren, L.F. Massuger, and M.E. Meijer-van Gelder Molecular profiling of platinum resistant ovarian cancer Int J Cancer 118 8 2006 1963 1971
31. K.L. Bennewith, and S. Dedhar Targeting hypoxic tumour cells to overcome metastasis BMC Cancer 11 2011 504
32. U. Krummrei, E.E. Baulieu, and B. Chambraud The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis Proc Natl Acad Sci USA 100 5 2003 2444 2449
33. C. Couture, H. Raybaud-Diogène, B. Têtu, I. Bairati, D. Murry, and J. Allard P53 and Ki-67 as markers of radioresistance in head and neck carcinoma Cancer 94 3 2002 713 722
34. F.M. Buffa, S.M. Bentzen, F.M. Daley, S. Dische, M.I. Saunders, and P.I. Richman Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy Clin Cancer Res 10 11 2004 3745 3754
35. H. Myoung, M.J. Kim, J.H. Lee, Y.J. Ok, J.Y. Paeng, and P.Y. Yun Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients Int J Oral Maxillofac Surg 35 11 2006 1005 1010
36. C.A. Fischer, M. Jung, I. Zlobec, E. Green, C. Storck, and L. Tornillo Co-overexpression of p21 and Ki-67 in head and neck squamous cell carcinoma relative to a significantly poor prognosis Head Neck 33 2 2011 267 273